Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) announced that its Phase 3 EASE LID clinical trial evaluating the company’s investigational compound ADS-5102 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE